| Primary |
| Osteitis |
11.3% |
| Abscess |
10.7% |
| Infection |
9.5% |
| Staphylococcal Infection |
8.3% |
| Arthritis Bacterial |
5.4% |
| Surgery |
5.4% |
| Device Related Infection |
4.8% |
| Hypertension |
4.8% |
| Intervertebral Discitis |
4.8% |
| Hiv Infection |
4.2% |
| Osteomyelitis |
4.2% |
| Streptococcal Infection |
4.2% |
| Osteoarthritis |
3.6% |
| Sepsis |
3.6% |
| Antibiotic Therapy |
3.0% |
| Endocarditis |
3.0% |
| Anxiety |
2.4% |
| Bone Pain |
2.4% |
| Hidradenitis |
2.4% |
| Pain |
2.4% |
|
| Rash Maculo-papular |
13.2% |
| Renal Failure Acute |
10.3% |
| Pyrexia |
7.4% |
| Urticaria |
7.4% |
| Renal Failure |
5.9% |
| Skin Test Negative |
5.9% |
| Thrombocytopenia |
5.9% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
4.4% |
| Pruritus |
4.4% |
| Rash |
4.4% |
| Toxic Skin Eruption |
4.4% |
| Acute Generalised Exanthematous Pustulosis |
2.9% |
| Cholangitis |
2.9% |
| Cholestasis |
2.9% |
| Confusional State |
2.9% |
| Hepatitis |
2.9% |
| Hepatitis Cholestatic |
2.9% |
| Hepatocellular Injury |
2.9% |
| Liver Injury |
2.9% |
| Oedema Peripheral |
2.9% |
|
| Secondary |
| Pneumonia Necrotising |
13.6% |
| Drug Use For Unknown Indication |
12.6% |
| Lung Disorder |
7.8% |
| Arthritis Bacterial |
7.4% |
| Product Used For Unknown Indication |
7.4% |
| Hiv Infection |
5.5% |
| Osteitis |
4.5% |
| Abscess |
4.2% |
| Endocarditis Staphylococcal |
3.9% |
| Erysipelas |
3.6% |
| Pneumonia |
3.6% |
| Prophylaxis |
3.6% |
| Osteomyelitis |
3.2% |
| Dermo-hypodermitis |
2.9% |
| Osteoarthritis |
2.9% |
| Pleurisy |
2.9% |
| Arthritis Infective |
2.6% |
| Infection |
2.6% |
| Mycoplasma Infection |
2.6% |
| Pain |
2.6% |
|
| Rash Maculo-papular |
19.1% |
| Agranulocytosis |
5.9% |
| Hepatic Failure |
5.9% |
| Pyrexia |
5.9% |
| Rhabdomyolysis |
5.9% |
| Skin Test Negative |
5.9% |
| Urticaria |
5.9% |
| Vascular Purpura |
5.9% |
| Jaundice |
4.4% |
| Renal Tubular Necrosis |
4.4% |
| Respiratory Distress |
4.4% |
| Acute Generalised Exanthematous Pustulosis |
2.9% |
| Dermatitis Exfoliative |
2.9% |
| Hepatitis Cholestatic |
2.9% |
| Polyuria |
2.9% |
| Rash Erythematous |
2.9% |
| Renal Impairment |
2.9% |
| Septic Shock |
2.9% |
| Skin Test Positive |
2.9% |
| Stevens-johnson Syndrome |
2.9% |
|
| Concomitant |
| Product Used For Unknown Indication |
25.2% |
| Hiv Infection |
10.1% |
| Drug Use For Unknown Indication |
9.2% |
| Cerebral Toxoplasmosis |
6.9% |
| Infection |
5.5% |
| Antibiotic Prophylaxis |
5.0% |
| Induction Of Anaesthesia |
4.6% |
| Abscess |
4.1% |
| Sepsis |
4.1% |
| Erysipelas |
3.2% |
| Pain |
3.2% |
| Endocarditis |
2.8% |
| Staphylococcal Infection |
2.8% |
| Pulmonary Embolism |
2.3% |
| Breast Cancer |
1.8% |
| Chronic Lymphocytic Leukaemia |
1.8% |
| Device Related Infection |
1.8% |
| Endocarditis Staphylococcal |
1.8% |
| Furuncle |
1.8% |
| Skin Infection |
1.8% |
|
| Renal Failure |
12.5% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
7.5% |
| Eosinophilia |
7.5% |
| Stevens-johnson Syndrome |
7.5% |
| Toxic Skin Eruption |
7.5% |
| Anaphylactic Shock |
5.0% |
| Pancytopenia |
5.0% |
| Rash |
5.0% |
| Rhabdomyolysis |
5.0% |
| Vascular Purpura |
5.0% |
| Vitreous Floaters |
5.0% |
| Weight Decreased |
5.0% |
| Weight Increased |
5.0% |
| Confusional State |
2.5% |
| Coronary Artery Stenosis |
2.5% |
| Death |
2.5% |
| Dermo-hypodermitis |
2.5% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
2.5% |
| Erysipelas |
2.5% |
| Hepatitis Cholestatic |
2.5% |
|
